Immunosuppressants (eg. MTX, RTX, MMF) can reduce immunogenicity to vaccines. VACIMRA study showing no difference in disease activity (beyond 1 month) and damage when MTX initiation was delayed by 1 month for the PCV13 pneumococcal vaccine. @RheumNow ABST1960 #ACR22 https://t.co/SKQ2qx3lJG

💤Our PsA patients are not sleeping well 💤 Abstract #0387 #ACR22 @RheumNow 😴 247 patients, sleep quality measured via PSQI 🛌 63% had poor sleep quality 💤 Worse sleep associated with female sex, higher disease activity, fatigue, anxiety/depression https://t.co/Wy20qx2Ah4

To taper or not to taper? In this prospective study by Dr. Cho, #SLE patients in complete remission had a longer time to flare upon drug tapering vs. those in LLDAS or clinical remission states. #ACR22 @RheumNow ABST#0996 #ACRBEst @rheumarhyme https://t.co/bSGlkc7Tvk

#ACR22 Abs 1752 finds rates of incident cancer did not differ between patients treated with anti-TNF and other bDMARDs or tsDMARDs. @RheumNow https://t.co/ycnQzrmAjw https://t.co/CSgDq2Gazg

Abs 1757 at #ACR22 finds women w/ gout have a higher risk of all-cause mortality, which is primarily driven by higher risk of CVD deaths. @RheumNow https://t.co/kPDL2VYRCN https://t.co/9qARr7T4fI

Abs L04 reviews novel humanized murine model of PsA disease phenotypes mediated by CD8 T Cells. Perhaps this is a step forward in personalized medicine. #ACR22 @RheumNow https://t.co/fPoElqFLI7 https://t.co/4pxBKoPnym

Prof Petri presents mortality data of their #lupus cohort 🔅55 yrs - ave age of death from all causes Top 4 common causes of death: 🔅SLE 🔅CVD 🔅Cancer 🔅Infection African-americans had ⬆️proportions of death from infections & renal causes #ACR22 @RheumNow #ABST2068 https://t.co/B5cAfZiRJp

Is sustained B cell depletion assoc w/⬇️dse flares in #lupus nephritis? In this study by Dr D Zisa, pts treated w/ BCA & had sustained Bcell depletion = ⬇️dse flares 👉Rapid repletion to BCC>100c/uL was assocd w/ 15.2x risk for flares #ACR22 @RheumNow ABST2065 https://t.co/ivSjm98YvZ

Is there a difference between IL-17i and TNFi in preventing radiographic progression in radiographic axSpA? Head to head study secukinumab vs. adalimumab biosimilar shows no sig difference with low radiographic progression. #ACRBest Abs#L15 @RheumNow #ACR22 https://t.co/UiHMtakaPz

Clinical pearl! Abs 1790 at #ACR22 finds bilateral US assessment of knees, wrists and hips provided the best sensitivity and specificity for diagnosing CPPD. @RheumNow https://t.co/3zlrNGCek4 https://t.co/hPK3eMH6iY

Are we screening & tx approp. for HBV in #IIM? Abstr #1864 found: - 78% IIM pts were screened for HBV (mean time 21 months from time of dx) - 73% Hep B Core Ab+ on RTX received Ppx tx - IIM pts Hep B Core Ab+ ↑ % +myositis spec ab and reach remission w/ IVIG @RheumNow #ACR22 https://t.co/QlQxGlkIhh

Denosumab for erosive hand OA? Abs L05 shows less erosive progression at week 24 with enhancement, including pain symptom improvement, at week 48. I can't wait to see more on this! #ACRbest #ACR22 @RheumNow https://t.co/aYb1biVgqt https://t.co/xHXj7nu1IJ